Stockscreener 앱 받기
2.65
0.76%
0.02
시장 영업 전:
2.66
0.01
+0.38%
전일 마감가:
$2.63
열려 있는:
$2.64
하루 거래량:
126.99K
Relative Volume:
0.09
시가총액:
$23.79M
수익:
$93.76M
순이익/손실:
$-13.68M
주가수익비율:
-1.0076
EPS:
-2.63
순현금흐름:
$8.77M
1주 성능:
+11.34%
1개월 성능:
+29.90%
6개월 성능:
+55.88%
1년 성능:
-3.64%
1일 변동 폭
$2.59
$2.6898
1주일 범위
$2.2969
$2.6898
52주 변동 폭
$0.95
$2.85
Aytu Biopharma Inc Stock (AYTU) Company Profile
명칭
Aytu Biopharma Inc
전화
(720) 437-6580
주소
7900 E. UNION AVENUE, DENVER
AYTU을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
AYTU
Aytu Biopharma Inc
|
2.65 | 22.94M | 93.76M | -13.68M | 8.77M | -2.63 |
|
ZTS
Zoetis Inc
|
152.82 | 68.32B | 9.29B | 2.52B | 2.28B | 5.57 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.66 | 46.55B | 30.08B | 710.16M | 4.45B | 0.2182 |
|
HLN
Haleon Plc Adr
|
9.85 | 43.80B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.33 | 19.01B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
306.41 | 13.79B | 2.99B | 1.21B | 1.13B | 25.06 |
Aytu Biopharma Inc Stock (AYTU) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-01 | 개시 | Lake Street | Buy |
| 2025-06-30 | 개시 | Ascendiant Capital Markets | Buy |
| 2021-03-30 | 개시 | Cantor Fitzgerald | Overweight |
| 2020-05-29 | 개시 | H.C. Wainwright | Buy |
Aytu Biopharma Inc 주식(AYTU)의 최신 뉴스
Aytu BioPharma Inc. Stock Analysis and ForecastPhenomenal trading returns - PrintWeekIndia
What drives Aytu BioPharma Inc. stock priceSuperior trading gains - Autocar Professional
What risks could impact Aytu BioPharma Inc. stock performanceHigh-velocity capital appreciation - jammulinksnews.com
What analysts say about Aytu BioPharma Inc. stock outlookJaw-dropping returns - jammulinksnews.com
Lake Street Sees Big Upside for Aytu Biosciences (AYTU) After EXXUA Acquisition - MSN
What analysts say about Aytu BioPharma Inc. stockUnstoppable trading performance - jammulinksnews.com
11 Best High Return Penny Stocks to Buy Now - Insider Monkey
Is Aytu BioPharma Inc. a good long term investmentOver 200% growth - Jammu Links News
What makes Aytu BioPharma Inc. stock price move sharplyWeekly Big Movers - beatles.ru
Why Aytu BioPharma Inc. stock attracts strong analyst attentionDouble Profit With Half Risk - beatles.ru
How Aytu BioPharma Inc. stock performs during market volatilityTrending Stock Alert - Newser
Aytu BioPharma Completes $15 Million Debt Refinancing - ACCESS Newswire
Aytu BioPharma (NASDAQ:AYTU) Downgraded by Wall Street Zen to Buy - Defense World
Aytu Boosts Liquidity with Eclipse Loan Extension - MSN
Aytu BioPharma (NASDAQ:AYTU) Now Covered by Lake Street Capital - Defense World
Aytu BioPharma (AYTU): Lake Street Initiates Coverage with Buy Rating | AYTU Stock News - GuruFocus
Lake Street Initiates Aytu BioPharma at Buy With $8 Price Target - MarketScreener
Aytu BioPharma (NASDAQ:AYTU) Coverage Initiated by Analysts at Ascendiant Capital Markets - Defense World
AYTU: Ascendiant Capital Initiates Coverage with 'Buy' Rating | AYTU Stock News - GuruFocus
This Starbucks Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Benzinga
Aytu BioPharma Receives Orphan Drug Designation from FDA for AR101 for Treatment of Vascular Ehlers-Danlos Syndrome - ACCESS Newswire
AYTU SEC FilingsAytu Biopharma Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Aytu BioPharma (NASDAQ:AYTU) Upgraded by Wall Street Zen to Strong-Buy Rating - Defense World
15 Best Growth Stocks to Invest in for the Next 5 Years - Insider Monkey
Aytu BioPharma Appoints Dr. Gerwin Westfield as Senior Vice President of Scientific Affairs to Support Commercialization of EXXUA(TM) - ACCESS Newswire
Aytu BioPharma Expands and Extends Lending Agreement with Eclipse Following Agreement to Commercialize First-in-Class Antidepressant EXXUA(TM) - ACCESS Newswire
Aytu BioScience Expands Lending Agreement for EXXUA Launch - TipRanks
Aytu BioPharma, Inc. (NASDAQ:AYTU) Sees Significant Decline in Short Interest - Defense World
Insider Spends US$100k Buying More Shares In Aytu BioPharma - simplywall.st
CEO & Director of Aytu BioPharma Joshua Disbrow Buys 77% More Shares - Yahoo Finance
Transcript : Aytu BioPharma, Inc.Special Call - MarketScreener
Aytu Biopharma CEO Joshua Disbrow acquires $99,999 in stock By Investing.com - Investing.com India
Aytu Biopharma Inc (AYTU) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.25%
0.75%
자본화:
|
볼륨(24시간):